Optipar (Paroxetine)

Paroxetine works by selectively blocking the serotonin transporter (SERT) on presynaptic neurons, preventing reuptake of serotonin. This raises serotonin levels in the synaptic cleft, enhancing serotonergic neurotransmission, which helps correct the neurochemical imbalances associated with depression and anxiety.

The specific dose of Optipar is determined by the prescribing clinician based on the patient’s diagnosis, severity, age, and response to therapy. Physicians typically start with a low dose and may adjust gradually, but exact dosing regimens should always follow the prescriber’s instructions.

Paroxetine is classified as a pregnancy‑category C drug, meaning potential risks to the fetus cannot be ruled out. It should be used only if the therapeutic benefit justifies the potential risk. Paroxetine is excreted in breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Optipar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Optipar (paroxetine) shares the core mechanism of serotonin reuptake inhibition with other SSRIs such as fluoxetine, sertraline, and escitalopram. Compared with some alternatives, paroxetine has a higher affinity for the transporter and may be associated with a greater incidence of certain side effects, like sexual dysfunction, but it can be advantageous for patients needing strong serotonergic activity.

Optipar tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain potency.

Optipar is taken orally, usually as a whole tablet with water. It can be taken with or without food, but patients should follow the prescribing clinician’s guidance on timing and whether to swallow with meals to minimize gastrointestinal discomfort.

The most serious risks include serotonin syndrome—a potentially life‑threatening condition when combined with other serotonergic agents—suicidal thoughts or behaviors, especially in young adults, severe hyponatremia, QT interval prolongation, and the emergence of mania or hypomania in susceptible individuals.

Optipar should be avoided in patients with known hypersensitivity to paroxetine or any SSRI, those currently taking monoamine oxidase inhibitors, individuals with uncontrolled narrow‑angle glaucoma, and patients with a history of severe cardiac arrhythmias related to QT prolongation. Contraindications also include concurrent use of pimozide or thioridazine.